Publications by authors named "P Lombardi"

Claim this Profile
L
Lenvatinib sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: The LEVIATHAN study.
Pasquale Lombardi, Jung Sun Kim, Giulia F Manfredi, Ciro Celsa, Claudia A M Fulgenzi

JHEP Rep· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of nutraceutical supplements containing L., (L.) Dunal and (L.) weber ex F.H.Wigg. on markers of inflammation, oxidative stress and gut microbiota in senior dogs.
Roberto Ciarcia, Consiglia Longobardi, Valeria Iervolino, Tommaso Manenti, Francesco Ferrucci, Pietro Lombardi

Front Vet Sci· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: An olive oil-derived NAE mixture (Olaliamid) improves liver and cardiovascular health, and decreases meta-inflammation in naturally obese dogs: a double-blind, randomized, placebo-controlled study.
Diego Piantedosi, Giada Morelli, Nadia Musco, Carlo Schievano, Maria Federica Della Valle, Pietro Lombardi

BMC Vet Res· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preliminary qualification of a machine learning-based assessment of the tumor immune infiltrate as a predictor of outcome in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab.
Bernhard Scheiner, Pasquale Lombardi, Antonio D'Alessio, Gwangil Kim, Masoud Tafavvoghi

J Immunother Cancer· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Race to the Bottom: A High-Volume Hospital Experience With Comprehensive Care for Joint Replacement.
John M Dundon, Nicholas C Brown, Lauren Gogel, Robyn Gilyard, Seohee Lee, Paul M Lombardi

J Arthroplasty· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis